ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CBMG Cellular Biomedicine Group Inc

19.74
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cellular Biomedicine Group Inc NASDAQ:CBMG NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 19.74 19.74 19.80 0 01:00:00

Investor Alert: Law Offices of Howard G. Smith Announces That a Class Action Has Been Filed on Behalf of Cellular Biomedicine...

08/06/2015 4:13pm

Business Wire


Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cellular Biomedicine Charts.

Law Offices of Howard G. Smith announces that a class action has been filed on behalf of investors of Cellular Biomedicine Group Inc. (NASDAQ:CBMG) who purchased shares between June 18, 2014 and April 7, 2015 (the “Class Period”). Purchasers of Cellular Biomedicine Group Inc. (“Cellular Biomedicine”) securities are encouraged to contact Howard G. Smith, Esq. to discuss your legal rights in the pending class action.

The complaint alleges that, among other allegations, the Company used paid stock promoters to achieve its $500 million valuation, but failed to disclose the use of promoters in its regulatory filings. On April 7, 2015, Seeking Alpha published a report on Cellular Biomedicine Group, which asserts that: (i) it has achieved an unsustainable valuation with paid stock promotion; (ii) its “CAR-T” technology has experienced patient deaths and is worthless; (iii) its founders face multiple allegations of dishonesty and are responsible for an alleged illegal offshore stem cell clinic; and (iv) it has multiple accounting and financial integrity issues. On this news, shares of Cellular Biomedicine Group fell sharply, declining $7.00 per share, or nearly 22%, to close on April 7, 2015 at $25.22 per share. The lawsuit seeks to recover damages suffered by investors as a result of the Company’s alleged fraud.

If you suffered a loss in Cellular Biomedicine you have until June 22, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

If you purchased shares of Cellular Biomedicine during the Class Period, contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. SmithHoward G. Smith, Esquire215-638-4847888-638-4847howardsmith@howardsmithlaw.comwww.howardsmithlaw.com

1 Year Cellular Biomedicine Chart

1 Year Cellular Biomedicine Chart

1 Month Cellular Biomedicine Chart

1 Month Cellular Biomedicine Chart

Your Recent History

Delayed Upgrade Clock